UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053357
Receipt number R000060904
Scientific Title Effect of consumption of the test food on visual function A Randomized, Double-blind, Placebo-controlled, Parallel-group Study
Date of disclosure of the study information 2024/02/16
Last modified on 2024/01/15 17:42:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of consumption of the test food on visual function
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study

Acronym

Effect of consumption of the test food on visual function

Scientific Title

Effect of consumption of the test food on visual function
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study

Scientific Title:Acronym

Effect of consumption of the test food on visual function

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effects of intake of the test food on visual function in healthy adults who are aware of their visual decline.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Evaluation of eye focusing

Key secondary outcomes

Evaluation of visual acuity, flicker fusion frequency, and visual analogue scale score


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Participants will intake one test beverages per day for twelve weeks. They will also get clinical tests before and 12 weeks after the beginning of the intervention.

Interventions/Control_2

Participants will intake one placebo beverages per day for twelve weeks. They will also get clinical tests before and 12 weeks after the beginning of the intervention.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Healthy Japanese men and women over 18 years old at the time of obtaining consent to participate in the study
2)Subjects who have given written consent(Consent to participate in MYCODE Research) to participate in MYCODE Research
3)Subjects who have be given sufficient explanation about the purpose and contents of this study, volunteer for voluntary participation with good understanding, and can consent to the study
4)Subjects who are aware of eye strain

Key exclusion criteria

1)Subjects with a history of alcoholism or mental illness
2)Subjects with insomnia
3)Subjects who have a habit of intaking supplements to improve visual function
4)Subjects who are receiving continuous pharmaceutical treatment
5)Subjects with previous and/or current medical history of serious disease (e.g. liver, kidney, heart, lung, blood)
6)Females who are pregnant and/or lactating, or those with willingness/intention to become pregnant during the study
7)Subjects that plan to have irregular life cycle (e.g. midnight shift work, long-term travel) and/or those with extremely irregular dining and sleep habits
8)Subjects who have a habit of intaking lactic acid bacteria beverages
9)Subjects who have a habit of intaking Food for Specified Health Uses and/or Foods with Functional Claims
10)Subjects with current or past experience of participating in other clinical studies and/or subjects who plan to participate in other clinical trials after obtaining consent to participate in the study
11)Subjects with refractive errors that have not been properly corrected
12)Subjects who have severe astigmatism
13)Subjects who have undergone LASIK surgery in the past
14)Subjects who are judged by the principal investigator to be unsuitable as the study

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Shoko
Middle name
Last name Sassa

Organization

Allm Inc.

Division name

Medical DX Solutions Department

Zip code

1500043

Address

16F Shibuya Mark City West, 1-12-1 Dogenzaka, Shibuya-ku, Tokyo

TEL

03-4361-2650

Email

IRB_dls@dena.com


Public contact

Name of contact person

1st name Takuya
Middle name
Last name Tajima

Organization

Allm Inc.

Division name

Medical DX Solutions Department

Zip code

1500043

Address

16F Shibuya Mark City West, 1-12-1 Dogenzaka, Shibuya-ku, Tokyo

TEL

03-4361-2650

Homepage URL


Email

IRB_dls@dena.com


Sponsor or person

Institute

Allm Inc.

Institute

Department

Personal name



Funding Source

Organization

NISSIN YORK CO.,LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

DeNA Life Science, Inc. Ethics Review Committee

Address

Shibuya Scramble Square 2 Chome-24-12 Shibuya, Shibuya City, Tokyo

Tel

03-6758-7200

Email

IRB_dls@dena.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 02 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 12 Month 20 Day

Date of IRB

2023 Year 12 Month 20 Day

Anticipated trial start date

2024 Year 02 Month 16 Day

Last follow-up date

2024 Year 08 Month 04 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 01 Month 15 Day

Last modified on

2024 Year 01 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060904


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name